Incomplete tolerance to the tumour-associated antigen MDM2

International Immunology

Volumn 16, Issue 2, 2004, Pages 327-334

  Ramírez, Francisco ^a   Ghani, Yasmeen ^a   Stauss, Hans ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Cytotoxic T lymphocyte; MDM2; Tumour

Indexed keywords

EPITOPE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PEPTIDE; PROTEIN MDM2; TUMOR ANTIGEN;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; EFFECTOR CELL; FEMALE; IMMUNIZATION; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL LINE; TUMOR IMMUNITY;

ANIMALS; ANTIGEN PRESENTATION; CYTOTOXICITY, IMMUNOLOGIC; EPITOPES; HISTOCOMPATIBILITY ANTIGENS CLASS I; IMMUNIZATION; IMMUNOTHERAPY; MICE; NEOPLASMS, EXPERIMENTAL; NUCLEAR PROTEINS; PEPTIDE FRAGMENTS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; SELF TOLERANCE; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, CYTOTOXIC; TUMOR ESCAPE;

EID: 1042292578     PISSN: 09538178     EISSN: None     Source Type: Journal    
DOI: 10.1093/intimm/dxh040     Document Type: Article

References (30)

1. Bueso Ramos, C. E., Yang, Y., deLeon, E., McCown, P., Stass, S. A. and Albitar, M. 1993. The human MDM-2 oncogene is overexpressed in leukaemias. Blood 82:2617.
2. Oliner, J. D., Kinzler, K. W., Metlzer, P. S., George, D. L. and Vogelstein, B. 1992. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 358:80.
3. Momand, J., Zambetti, G. P., Olson, D. C., George, D. L. and Levine, A. J. 1992. The MDM-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69:1237.
4. Ohashi, P. S., Oehen, S., Buerki, K., Pircher, H., Ohashi, T. C., Odermatt, B., Malissen, B., Zinkernagel, R. M. and Hengartner, H. 1991. Ablation of tolerance and induction of diabetes by virus infection in viral antigen transgenic mice. Cell 65:305.
5. Arnold, B., Schronrich, G. and Hammerling, G. J. 1993. Multiple levels of peripheral tolerance. Immunol. Today 14:12.
6. Bakker, A. B. H., Schreurs, M. W. J., de Boer, A. J., Kawakami, Y., Rosenberg, S. A., Adema, G. J. and Figdor, C. G. 1994. Melanocyte lineage-specific antigen gp100 is recognized by melanocyte-derived tumour-infiltrating lymphocytes. J. Exp. Med. 179:1005.
7. Cox, A. L., Skipper, J., Chen, Y., Henderson, R. A., Darrow, T. L., Shabanowitz, J., Engelhard, V. H., Hunt, D. F. and Slingluff, C. L. 1994. Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science 264:716.
8. Boon, T. J., Cerottini, J. C., Van den Eynde, B., Van der Bruggen, P. and Van Pel, A. 1994. Tumor-antigens recognized by T-lymphocytes. Annu. Rev. Immunol. 12:337.
9. Vierboom, M. P. M., Nijman, H. W., Offringa, R., van der Boot, E. I. H., van Hall, T., van der Broek, L., Fleuren, G. J., Keneman, P., Kast, W. M. and Melief, C. J. M. 1997. Tumor eradication by wild-type p53-specific cytotoxic T lymphocytes. J. Exp. Med. 186:695.
10. Molldrem, J. J., Clave, E., Jiang, Y. Z., Mavroudis, D., Raptis, A., Hensel, N., Agarwala, V. and Barret, A. J. 1997. Cytotoxic T lymphocytes specific for a nonpolymorphic proteinase 3 peptide preferentially inhibit chronic myeloid leukemia colony-forming units. Blood 90:2529.
11. + progenitor cells by cytotoxic T lymphocytes specific for WT1. Blood 95:2198.
12. Dahl, A. M., Beverley, P. C. L. and Stauss, H. J. 1996. A synthetic peptide derived from the tumor-associated protein mdm2 can stimulate autoreactive, high avidity cytotoxic T lymphocytes that recognize naturally processed protein. J. Immunol. 157:239.
13. Sadovnikova, E. and Stauss, H. J. 1996. Peptide-specific cytotoxic T lymphocytes restricted by nonself major histocompatibility complex class I molecules: reagents for tumor immunotherapy. Proc. Natl Acad. Sci. USA 93:13114.
14. Ljunggren, H. G. and Kahre, K. 1985. Host resistance directed selectively against H-2 deficient lymphoma variants: analysis of the mechanism. J. Exp. Med. 162:1745.
15. Sette, A., Vitiello, A., Reherman, B., Fowler, P., Nayersina, R., Kast, W. M., Melief, C. J. M., Oseroff, C., Yuan, L., Ruppert, J., Sidney, J., del Guercio, M. F., Southwood, S., Kubo, R. T., Chesnut, R. W., Grey, H. M. and Chisari, F. V. 1994. The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes. J. Immunol. 153:5586.
16. Kast, W. M., Roux, L., Curren, J., Blom, H. J. J., Voordouw, A. C., Meloen, R. H., Kolakofsky, D. and Melief, C. J. M. 1991. Protection against lethal Sendai virus infection by in vivo priming of virus-specific cytotoxic T lymphocytes with a free synthetic peptide. Proc. Natl Acad. Sci. USA 88:2283.
17. Alexander-Miller, M. A., Leggat, G. R. and Berzofsky, J. A. 1996. Selective expansion of high- or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy. Proc. Natl Acad. Sci. USA 93:4102.
18. Zeh, H. J., Perry-Lalley, D., Dudley, M. E., Rosenberg, S. A. and Yang, J. C. 1999. High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumour efficacy. J. Immunol. 162:989.
19. Ossendorp, F., Mengede, E., Camps, M., Filius, R. and Melief, C. J. M. 1998. Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumours. J. Exp. Med. 187:693.
20. Alexander-Miller, M. A., Leggat, G. R., Sarin, A. and Berzofsky, J. A. 1996. Role of antigen, CD8, and cytotoxic T lymphocyte (CTL) avidity in high dose antigen induction of apoptosis of effector CTL. J. Exp. Med. 184:485.
21. Zajac, A. J., Blattman, J. N., Murali-Krishna, K., Sourdive, D. J. D., Suresh, M., Altman, J. D. and Ahmed, R. 1998. Viral immune evasion due to persistence activated T cells without effector function. J. Exp. Med. 188:2205.
22. + T cell function during in vivo memory or tolerance induction. Immunity 8:581.
23. + T cell tolerance to a tumor-associated antigen is maintained at the level of expansion rather than effector function. J. Exp. Med. 195:1407.
24. + T cell: receptor-dependent cytolysis in the absence of interleukin-2 production. Science 251:1128.
25. Yee, C., Savage, P. A., Lee, P. P., Davis, M. M. and Greenberg, P. D. 1999. Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramer. J. Immunol. 162:2227.
26. Echchakir, H., Dorothee, G., Vergnon, I., Menez, J., Chouaib, S. and Mami-Chouaib, F. 2002. Cytotoxic T lymphocytes directed against a tumor-specific mutated antigen display similar HLA tetramer binding but distinct functional avidity and tissue distribution. Proc. Natl Acad. Sci. USA 99:9358.
27. Webb, S., Morris, C. and Sprent, J. 1990. Extrathymic tolerance of mature T cells: clonal elimination as a consequence of immunity. Cell 63:1249.
28. + T cells undergoing peripheral deletion in response to cross-presentation of self-antigen. J. Exp. Med. 194:707.
29. Toes, R. E. M., van der Boot, E. I. H., Schoenberger, S. P., Drijfhout, J. W., van Bloois, L., Storm, G., Kast, W. M., Offringa, R. and Melief, C. J. M. 1998. Enhancement of tumour outgrowth through CTL tolerization after peptide vaccination is avoided by peptide presentation on dendritic cells. J. Immunol. 160:4449.
30. Diehl, L., den Boer, A. T., Schoenberger, S. P., van der Voort, E. I. H., Schumacher, T. N. N., Melief, C. J. M., Offringa, R. and Toes, R. E. M. 1999. CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy. Nat. Med. 5:774.